Molecular Medicine

, Volume 17, Issue 11–12, pp 1275–1284 | Cite as

AHR Regulates WT1 Genetic Programming during Murine Nephrogenesis

  • M. Hadi Falahatpisheh
  • Adrian Nanez
  • Kenneth S. Ramos
Research Article


Mounting evidence suggests that the blueprint of chronic renal disease is established during early development by environmental cues that dictate alterations in differentiation programming. Here we show that aryl hydrocarbon receptor (AHR), a ligand-activated basic helix-loop-helix-PAS homology domain transcription factor, disrupts murine renal differentiation by interfering with Wilms tumor suppressor gene (WT1) signaling in the developing kidney. Embryonic kidneys of C57BL/6J Ahr−/− mice at gestation d (GD) 14 showed reduced condensation in the nephrogenic zone and decreased numbers of differentiated structures compared with wild-type mice. These deficits correlated with increased expression of the (+) 17aa Wt1 splice variant, decreased mRNA levels of Igf-1 rec., Wnt-4 and E-cadherin, and reduced levels of 52 kDa WT1 protein. AHR knockdown in wild-type embryonic kidney cells mimicked these alterations with notable increases in (+) 17aa Wt1 mRNA, reduced levels of 52 kDa WT1 protein, and increased (+) 17aa 40-kDa protein. AHR downregulation also reduced Igf-1 rec., Wnt-4, secreted frizzled receptor binding protein-1 (sfrbp-1) and E-cadherin mRNAs. ln the case of Igf-1 rec. and Wnt-4, genetic disruption was fully reversed upon restoration of cellular Wt1 protein levels, confirming that functional interactions between AHR and Wt1 represent a likely molecular target for renal developmental interference.



This study was supported by NIH Grants ES04917, ES012542 and ES014443. The authors wish to thank Steven Potter (Children’s Hospital Medical Center, Cincinnati, OH, USA) for providing the mK3 and mK4 cell lines, Aart G Jochemsen (Leiden University Medical Center, Leiden, The Netherlands) for Wt1 cDNA plasmids and Vilius Stribinskis for helpful discussions. The assistance of Marlene Steffen and Diego Montoya is gratefully acknowledged.


  1. 1.
    Barker DJ, Winter PD, Osmond C, Margetts B, Simmonds SJ. (1989) Weight in infancy and death from ischaemic heart disease. Lancet. 2:577–80.CrossRefGoogle Scholar
  2. 2.
    Lim K, Armitage JA, Stefanidis A., Oldfield BJ, Black MJ. (2011). Intrauterine growth restriction in the absence of postnatal ‘catch-up’ growth leads to improved whole body insulin sensitivity in rat offspring. Pediatr. Res. [Epub ahead of print].Google Scholar
  3. 3.
    Menendez-Castro C, et al. (2011), Early and late postnatal myocardial and vascular changes in a protein restriction rat model of intrauterine growth restriction. PLoS One. 6:e20369.CrossRefPubMedCentralGoogle Scholar
  4. 4.
    Nanez A, Ramos KS. (2010) Introduction and Overview of Receptor Systems. In: Comprehensive Toxicology. 2nd ed. Vol. 2. McQueen CA (editor in chief). Elsevier, San Diego, pp. 71–80. Available at: Scholar
  5. 5.
    Falahatpisheh MH, Ramos KS. (2003) Ligand-activated Ahr signaling leads to disruption of nephrogenesis and altered Wilms’ tumor suppressor mRNA splicing. Oncogene. 22:2160–71.CrossRefGoogle Scholar
  6. 6.
    Bittinger MA, Nguyen LP, Bradfield CA. (2003) Aspartate aminotransferase generates proagonists of the aryl hydrocarbon receptor. Mol. Pharmacol. 64:550–6.CrossRefGoogle Scholar
  7. 7.
    Kreidberg JA, et al. (1993) WT-1 is required for early kidney development. Cell. 74:679–91.CrossRefGoogle Scholar
  8. 8.
    Menke AL, van der Eb AJ, Jochemsen AG. (1998) The Wilms’ tumor 1 gene: oncogene or tumor suppressor gene? Int. Rev. Cytol. 181:151–212.CrossRefGoogle Scholar
  9. 9.
    Iben S, Royer-Pokora B. (1999) Analysis of native WT1 protein from frozen human kidney and Wilms’ tumors. Oncogene. 18:2533–6.CrossRefGoogle Scholar
  10. 10.
    Wang ZY, Qiu QQ, Gurrieri M, Huang J, Deuel TF (1995). Wt1, the Wilm’s tumor suppressor gene product, represses transcription through an interactive nuclear protein. Oncogene. 10:1243–7.PubMedGoogle Scholar
  11. 11.
    Englert C, et al. (1995). Truncated wt1 mutants alter the subnuclear localization of the wild-type protein. PNAS. 92:11960–4.CrossRefGoogle Scholar
  12. 12.
    Wagner KD, Wagner N, Schedl A. (2003) The complex life of WT1. J. Cell Sci. 116:1653–8.CrossRefGoogle Scholar
  13. 13.
    Hammes A, et. al. (2001) Two splice variants of the Wilms’ tumor 1 gene have distinct functions during sex determination and nephron formation. Cell. 106:319–29.CrossRefGoogle Scholar
  14. 14.
    Barbaux S, et al. (1997). Donor splice-site mutations in WT1 are responsible for Frasier syndrome. Nat. Genet. 17:467–70.CrossRefGoogle Scholar
  15. 15.
    Richard DJ, Schumacher V, Royer-Pokora B, Roberts SGE. (2001) Par4 is a coactivator for a splice isoform-specific transcriptional activation domain in WT1. Genes. Dev. 15:328–39.CrossRefPubMedCentralGoogle Scholar
  16. 16.
    Renshaw J, King-Underwood L, Pritchard-Jones K. (1997) Differential splicing of exon 5 of the Wilms tumour (WT1) gene. Genes Chromosomes Cancer. 19:256–66.CrossRefGoogle Scholar
  17. 17.
    Reiners Jr JJ, Jones CL, Hong N, Myrand SP (1998) Differential induction of Cyp1a1, Cyp1b1, Ahd4, and Nmo1 in murine skin tumors and adjacent normal epidermis by ligands of the aryl hydrocarbon receptor. Mol. Carcinog. 21:135–46.CrossRefGoogle Scholar
  18. 18.
    Hosono S, et al. (2000) E-cadherin is a WT1 target gene. J. Biol. Chem. 275:10943–53.CrossRefGoogle Scholar
  19. 19.
    Peinnequin A, et. al. (2004) Rat pro-inflammatory cytokine and cytokine related mRNA quantification by real-time polymerase chain reaction using SYBR green. BMC Immunol. 5:3.CrossRefPubMedCentralGoogle Scholar
  20. 20.
    Valerius MT, Patterson LT, Witte DP, Potter SS. (2002) Microarray analysis of novel cell lines representing two stages of metanephric mesenchyme differentiation. Mech. Dev. 112:219–32.CrossRefGoogle Scholar
  21. 21.
    Whitlock Jr JP. (1999) Induction of cytochrome P4501A1. Annu. Rev. Pharmacol. Toxicol. 39:103–25.CrossRefGoogle Scholar
  22. 22.
    Abbott BD, Perdew GH, Buckalew AR, Birnbaum LS. (1994) Interactive regulation of Ah and glucocorticoid receptors in the synergistic induction of cleft palate by 2,3,7,8-tetrachlorodibenzo-p-dioxin and hydrocortisone. Toxicol. Appl. Pharmacol. 128:138.CrossRefGoogle Scholar
  23. 23.
    Bryant PL, Clark GC, Probst MR, Abbott BD. (1997) Effects of TCDD on Ah receptor, ARNT, EGF, and TGF-alpha expression in embryonic mouse urinary tract. Teratology 55:326–37.CrossRefGoogle Scholar
  24. 24.
    Pritchard-Jones K, et. al. (1990) The candidate Wilms’ tumour gene is involved in genitourinary development. Nature. 346:194–7.CrossRefGoogle Scholar
  25. 25.
    Nanez A, Ramos IN, Ramos KS. (2011) A mutant AHR allele protects the embryonic kidney from hydrocarbon-induced deficits in fetal programming. Environ. Health Perspect. 2011 Jul 29 [Epub ahead of print].Google Scholar
  26. 26.
    Teneng I, Stribinskis V, Ramos KS. (2007) Context specific regulation of LINE-1. Genes Cells. 12:1101–10.CrossRefGoogle Scholar
  27. 27.
    Ramos KS, Montoya-Durango DE, Teneng I, Nanez A, Stribinskis V. (2011) Epigenetic control of embryonic renal cell differentiation by L1 retrotransposon. Birth Defects Res. A. Clin. Mol. Teratol. 91:693–702.CrossRefPubMedCentralGoogle Scholar
  28. 28.
    Thackaberry EA, et al. (2003) Insulin regulation in AhR-null mice: embryonic cardiac enlargement, neonatal macrosomia, and altered insulin regulation and response in pregnant and aging AhR-null females. Toxicol. Sci. 76:407–17.CrossRefGoogle Scholar
  29. 29.
    Sim EUH, et al. (2002) Wnt-4 regulation by the Wilms’ tumor suppressor gene, WT1. Oncogene. 21:2948–60.CrossRefGoogle Scholar
  30. 30.
    Werner H, Roberts Jr CT, Rauscher 3rd FJ, LeRoith D. (1996) Regulation of insulin-like growth factor I receptor gene expression by the Wilms’ tumor suppressor WT1. J. Mol. Neurosci. 7:111–23.CrossRefGoogle Scholar
  31. 31.
    Duong Van Huyen JP, et al. (2003) Spatiotemporal distribution of insulin-like growth factor receptors during nephrogenesis in fetuses from normal and diabetic rats. Cell Tissue Res. 314:367–79.CrossRefGoogle Scholar
  32. 32.
    Stark K, Vainio S, Vassileva G, McMahon AP. (1994) Epithelial transformation of metanephric mesenchyme in the developing kidney regulated by Wnt-4. Nature. 372:679.CrossRefGoogle Scholar
  33. 33.
    Vincan E. (2004) Frizzled/WNT signalling: the insidious promoter of tumour growth and progression. Front. Biosci. 9:1023–34.CrossRefGoogle Scholar
  34. 34.
    Yoshino K, et al. (2001) Secreted Frizzled-related proteins can regulate metanephric development. Mech. Dev. 102:45.CrossRefGoogle Scholar
  35. 35.
    Chesire DR, Dunn TA, Ewing CM, Luo J, Isaacs WB. (2004) Identification of Aryl Hydrocarbon Receptor as a putative Wnt/ta-Catenin pathway target gene in prostate cancer cells. Cancer Res. 64:2523–33.CrossRefGoogle Scholar
  36. 36.
    Natoli TA, et. al. (2002) A mutant form of the Wilms’ tumor suppressor gene WT1 observed in Denys-Drash Syndrome interferes with glomerular capillary development. J. Am. Soc. Nephrol. 13:2058–67.CrossRefGoogle Scholar
  37. 37.
    Hewitt SM, Saunders GF. (1996) Differentially spliced exon 5 of the Wilms’ tumor gene WT1 modifies gene function. Anticancer Res. 16:621–6.PubMedGoogle Scholar
  38. 38.
    Reiner J, Jones Jr C, Hong N, Myrand S. (1994) Differential induction of cyp1A1, cyp1B1, ahd4, and nmo1 in murine skin tumors and adjacent normal epidermis by ligands of the aryl hydrocarbon receptor. Mol. Carcinog. 21:135–46.CrossRefGoogle Scholar

Copyright information

© The Feinstein Institute for Medical Research 2011

Authors and Affiliations

  • M. Hadi Falahatpisheh
    • 1
  • Adrian Nanez
    • 1
  • Kenneth S. Ramos
    • 1
  1. 1.Department of Biochemistry and Molecular BiologyUniversity of Louisville School of MedicineLouisvilleUSA

Personalised recommendations